Sangamo BioSciences (SGMO)

Company Description

Sangamo BioSciences is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase II clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. SGMO’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. SGMO’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation.


501 Canal Boulevard
Richmond, California 94804
United States



Get BioInvest's perspective on Sangamo's CEO

Latest Company News

These Stock's are Flying High, But Don't Go Contrarian Yet: Sangamo ... StockNewsJournal - 15 hours ago Sangamo Therapeutics, Inc. (NASDAQ:SGMO) market capitalization at present is $776.64M at the rate of $10.25 a share. The firm's price-to-sales ratio was noted 37.84 in contrast with an overall industry average of 88.48. [...]
Fri, Aug 18, 2017 1:07:00 PM, Continue reading at the source
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock Traded 10.3% Above Its 50 Day ... Modern Readers - 18 hours ago Here is the rundown on market activity for Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Curt A. Iii Herberts, Sr.VP & Chief Business Officer sold $150,000 worth of shares at an average price of $10.00 on Fri the 14th. The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stake Decreased by ... - ExpressNewsline Analyst Commentary On Sangamo Therapeutics, Inc. (SGMO), Upland Software, Inc ... - Post Analyst [...]
Fri, Aug 18, 2017 9:45:00 AM, Continue reading at the source
What Lies Ahead For CECO Environmental Corp. (CECE) And Sangamo Therapeutics ... Post Analyst - Aug 17, 2017 CECO Environmental Corp. (NASDAQ:CECE) traded at an unexpectedly low level on 08/16/2017 when the stock experienced a 3.1% gain to a closing price of $7.31. [...]
Thu, Aug 17, 2017 5:26:00 PM, Continue reading at the source
Sangamo Therapeutics: The Breakthrough In Gene Therapy Seeking Alpha - Aug 17, 2017 Sangamo Therapeutics' accomplishments to date have helped to draw integrity to its operations and raise its profile against common competitors in the space (QURE, GSK, ONCE, BMRN, BLUE, BIVV (a pure-play hemophilia company). Principally, Sangamo ... Sangamo Therapeutics, Inc. (SGMO): What's the Story? - StockNewsJournal Going Through the Chart for Sangamo Therapeutics, Inc. (SGMO) - Economic News [...]
Thu, Aug 17, 2017 1:52:00 PM, Continue reading at the source
Price Alert: Sangamo Therapeutics Inc (NASDAQ:SGMO) Stock Nears Resistance ... CML News - Aug 15, 2017 Price Alert: Sangamo Therapeutics Inc (NASDAQ:SGMO) has now crossed into technical strength -- watch the technical oscillators for momentum gaps. [...]
Tue, Aug 15, 2017 8:15:00 PM, Continue reading at the source
Stunning stock of yesterday: Sangamo Therapeutics, Inc. (SGMO) Hot Stocks Point - Aug 15, 2017 USA based company, Sangamo Therapeutics, Inc. (SGMO)'s latest closing price distance was at 115.72% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 34.24% and 28.07% compared with the 20 Day ... [...]
Tue, Aug 15, 2017 8:37:00 AM, Continue reading at the source
Sangamo Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire (press release) - Aug 9, 2017 Established an exclusive, global collaboration and license agreement with Pfizer Inc. for the development and commercialization of gene therapy programs for hemophilia A, including SB-525. Sangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow ... - Markets Insider Is It Time to go for Weyerhaeuser Co. (WY), Sangamo Therapeutics, Inc. (SGMO)? - StockNewsJournal [...]
Wed, Aug 09, 2017 8:03:00 PM, Continue reading at the source
Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast PR Newswire (press release) - Aug 2, 2017 RICHMOND, Calif., Aug. 2, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its second quarter 2017 financial results after the market closes on Wednesday, August 9, 2017. Sangamo Therapeutics, Inc. (SGMO) Position Held by Public Employees Retirement ... - Week Herald Institutional Investors Are Buying Sangamo Biosciences Inc (NASDAQ:SGMO) - BZ Weekly [...]
Wed, Aug 02, 2017 8:03:00 PM, Continue reading at the source
Is Sangamo Therapeutics Pointing Toward Success? Seeking Alpha - Jun 29, 2017 Sangamo Therapeutics (SGMO) is a $650 million dollar market cap company focused on gene and cell therapies, including conducting the first-ever genome editing studies in clinical trials. [...]
Thu, Jun 29, 2017 11:15:00 AM, Continue reading at the source
Why Sangamo Therapeutics Inc. Jumped Higher Today Motley Fool - May 12, 2017 More likely, today's jump is from investors short Sangamo Therapeutics who need to buy shares to close their short positions. Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene ... - PR Newswire (press release) Sangamo's Gene Therapy Gets Pfizer Stamp Of Approval - Seeking Alpha [...]
Fri, May 12, 2017 8:15:00 PM, Continue reading at the source